Pharmaceutical manufacturers of Mitomycin

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Sicor, situated in the northern region of Italy, is a component of the Teva API business and offers a worldwide platform for the production and promotion of APIs for injectable, inhalation, topical, and nasal products. These specialized facilities possess a significant level of skill, manufacturing approximately 60 active pharmaceutical ingredients.

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise featuring whole chain, multi-regional integration of research, production and marketing as well as development of drug substances and preparations. In 2000, an A-share was issued in order to enter the stock market as a state-owned listed company. As of 2021, Hisun Pharmaceutical is now one of the largest producers of antibiotics and anti-tumor drugs in China and has been listed in the Top 500 Chinese manufacturing enterprises and the Top 100 Chinese pharmaceutical enterprises multiple times. In 2020 Hisun Pharmaceuticals received special recognition from the Joint Prevention and Control Team from the State Council of the People’s Republic of China for their extraordinary efforts in the fight against the epidemic, and Hisun Pharmaceutical was awarded with the “Anti COVID-19 Advanced Collective in Ministry of Industry and Information Technology".

We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis seen in recent years, we anticipate the development of new biotechnology processes and products from fermentation, a technology which humankind has been utilizing since time immemorial.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Concord Biotech Limited is a prominent vertically integrated, research and development-driven biotechnological powerhouse that produces Active Pharmaceutical Ingredients using fermentation and semi-synthetic methods, as well as Finished formulations. Established in 2000, Concord has evolved from a single-product enterprise to a wide-ranging solution provider, offering products across varied therapeutic segments. Concord is internationally recognized for its products and holds a strong presence in over 50 countries worldwide with effective distribution infrastructure in markets such as North America, Europe, Japan, Central & Latin America, Africa, Australia, and other regions.

Zhejiang Huida Biotech Co., Ltd. is situated in Hangzhou, within Zhejiang Province. It was founded in 2020 and operates as a subsidiary of Huadong Medicine Co., Ltd. The organization specializes in the exploration and formulation of microbial active pharmaceutical substances (APIs), intermediates, and extensive health products. It stands as a technologically inventive research enterprise in the field of fermentation products. Leveraging robust R&D capabilities, the corporation delivers top-notch technology, service, and products to its global clientele by uncovering and nurturing the most valuable microbial metabolites.

Wuxi Fortune Pharmaceutical Co Ltd focuses on the development and manufacture of active pharmaceutical ingredients (API) and finished drugs, aiming to deliver top-notch products and services to its customers. The company boasts an impeccable quality management system, state-of-the-art machinery, exceptional product quality, and comprehensive support facilities. It has obtained Chinese GMP and European GMP certifications and has successfully met the ISO14001 environmental management standards.